FRM
ALNY icon

Fox Run Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fox Run Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,465
Closed -$668K – 880
2025
Q3 		$668K Buy
1,465
+202
+16% +$82.3K 0.1% 379
2025
Q2 		$412K Buy
+1,263
New +$349K 0.07% 543
2025
Q1 		– Sell
-2,809
Closed -$661K – 889
2024
Q4 		$661K Sell
2,809
-76
-3% -$20K 0.12% 342
2024
Q3 		$793K Buy
+2,885
New +$751K 0.18% 195
2024
Q2 		– Sell
-2,988
Closed -$447K – 757
2024
Q1 		$447K Buy
2,988
+1,532
+105% +$256K 0.1% 408
2023
Q4 		$279K Buy
+1,456
New +$248K 0.07% 521
2023
Q3 		– Sell
-2,797
Closed -$531K – 688
2023
Q2 		$531K Buy
+2,797
New +$555K 0.15% 268
2021
Q3 		– Sell
-1,947
Closed -$330K – 452
2021
Q2 		$330K Buy
+1,947
New +$285K 0.3% 140
2019
Q3 		– Sell
-9,514
Closed -$690K – 347
2019
Q2 		$690K Buy
+9,514
New +$730K 0.46% 21
2018
Q3 		– Sell
-9,836
Closed -$969K – 555
2018
Q2 		$969K Buy
+9,836
New +$976K 0.31% 37
2018
Q1 		– Sell
-2,800
Closed -$356K – 698
2017
Q4 		$356K Sell
2,800
-1,800
-39% -$226K 0.1% 404
2017
Q3 		$540K Buy
+4,600
New +$393K 0.15% 261
2017
Q1 		– Sell
-6,900
Closed -$258K – 554
2016
Q4 		$258K Sell
6,900
-800
-10% -$33.5K 0.14% 350
2016
Q3 		$522K Buy
+7,700
New +$543K 0.31% 89

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fox Run Management's ALNY Position: Q4 2025 in Review

Fox Run Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 1,465 shares — an estimated $668K sold.

Fox Run Management first reported a position in ALNY in Q3 2016 and held it in 14 quarters. The position peaked at $969K in Q2 2018. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Fox Run Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Fox Run Management sold 1,465 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $668K.
  • Fox Run Management first reported a position in Alnylam Pharmaceuticals in Q3 2016 and held it in 14 quarters.
  • Fox Run Management's Alnylam Pharmaceuticals position peaked at $969K in Q2 2018.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.